MedTrace Logo

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

NCT02167204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-01-13

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring cell proliferation in patients with brain tumors. Comparing results of diagnostic procedures done before, during, and after treatment may help doctors measure tumor growth and plan the best treatment.

Conditions

  • Metastatic Malignant Neoplasm in the Brain
  • Primary Brain Neoplasm
  • Recurrent Brain Neoplasm

Interventions

PROCEDURE

Computed Tomography

Undergo 18F-FLT PET/CT

RADIATION

Fluorothymidine F-18

Undergo 18F-FLT PET/CT

PROCEDURE

Positron Emission Tomography

Undergo 18F-FLT PET/CT

Sponsors & Collaborators

Principal Investigators

  • Jason Rockhill · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2019-01-21
Completion
2019-01-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02167204 on ClinicalTrials.gov